• Seit 11/2016: Chefarzt Gynäkologie, Schwerpunkt Gynäkologische Onkologie und Spezielle operative Gynäkologie, Rotkreuzklinikum München Frauenklinik
• Seit 08/2016: Medizinische Leitung mit PD Dr. Pölcher der Praxis für Senologie und Gynäkologische Onkologie, Brustzentrum Taxisstraße, www.gynonko.de
• 2012: Leiter des interdisziplinären Brustzentrums am Rotkreuzklinikum München (zertifiziert nach DKG)
• 2012: Sprecher/Koordinator der Hauptabteilung Gynäkologie und Leitender Arzt der Abteilung für Senologie am Rotkreuzklinikum München
• 2010: Gemeinschaftspraxis Dr. Hamann, PD Dr. Braun, PD Dr. Pölcher (ab 2011), Renatastraße München, und Konsiliararzt am Rotkreuzklinikum München Frauenklinik Taxisstraße
• 2010: Erlangung der „Venia Legendi" der Hohen Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn für das Lehrgebiet Gynäkologie und Geburtshilfe, Habilitationsschrift: „Klinische Anwendung neuer diagnostischer Verfahren beim Mammakarzinom"
• 2/2008 – 3/2010: Leiter der Bonner Projektgruppe Mammakarzinom am Comprehensive Cancer Center (CIO) der Universitäten Köln/Bonn
• 11/2005 – 3/2010: Leiter der Projektgruppe Mammakarzinom am Tumorzentrum Bonn
• 11/2004 – 3/2010: Leiter des Brustzentrums an der Universitäts-Frauenklinik Bonn
• 9/2004 – 3/2010: Oberarzt an der Universitäts-Frauenklinik Bonn
• 10/2003: Facharztanerkennung: Gynäkologie und Geburtshilfe
• 2/2002 – 10/2003: Facharztausbildung an der Universitäts-Frauenklinik Bonn (Direktor: Prof. Dr. med. Walther Kuhn)
• 1/2001 – 2/2002: Assistenzarzt an der Frauenklinik Bogenhausen/München (Direktor: Prof. Dr. med. Joachim Gnirs)
• 6/1998 – 12/2000: AIP/Assistenzarzt an der Universitäts-Frauenklinik der TU München am Klinikum rechts der Isar (Direktor: Prof. Dr. med. Henner Graeff)
• 1/2000: Dissertation: „Sonographische und dopplersonographische Charakterisierung von Brusttumoren"
• 12/1999: Approbation
• 1991 – 1998: Studium der Humanmedizin an der Universität Regensburg bis Physikum und an der Technischen Universität München

• Botschafter Frauenselbsthilfe Krebs, Landesverband Baden-Württemberg/Bayern
• Brustkrebs Deutschland e. V., Mitglied im ärztlichen Beirat
• Deutsche Krebsgesellschaft e. V. (DKG)
• Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG)
• Deutsche Gesellschaft für Senologie e. V. (DGS)
• Arbeitsgemeinschaft für Gynäkologische Onkologie e. V. (AGO)
• Deutsche Gesellschaft für Ultraschall in der Medizin e. V. (DEGUM)
• Vorstandsmitglied in der Projektgruppe „Mammakarzinome" des Tumorzentrums München
• Operatives Mitglied der Tumorkonferenz des Mammographie-Screeningprogramms im Radiologischen Zentrum Pasing
• Breast Competence Club der European Academy of Senology
• European Association for Predictive, Preventive and Personalised Medicine (EPMA)
• American Society of Clinical Oncology (ASCO)

• Spezielle operative Gynäkologie
• Gynäkologische Onkologie
• Operative und medikamentöse Behandlung des Mammakarzinoms

Publikationen/Abstracts, Co-Autorenschaften (Stand: 06/2026)

• Loibl S, Untch M, Huober J, Schaser V, Braun M, Denkert C, Hartkopf A, Blohmer JU, Hanusch C, Link T, Reinisch M, Zahm DM, Weide R, Bjelic-Radisic V, Staib P, Tesch H, Rhiem K, Lorenz R, Rey J, Schneeweiss A. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. J Clin Oncol. 2026 Apr 20:JCO2502311. doi: 10.1200/JCO-25-02311. PMID: 42008768.
• Gluz O, Nitz U, Christgen M, Kuemmel S, Braun M, Thill M, Wuerstlein R, Link T, Aktas B, Lüdtke-Heckenkamp K, Zaiss M, Bjelic-Radisic V, Just M, Veselinovic K, Vincent M, Baehner R, Wujak L, Warm M, Schumacher C, Schem C, Forstbauer H, Krauss K, Hoffmann O, Graeser M, Hartkopf A, Kates R, Zu Eulenburg C, Jóźwiak K, Burmeister S, Schmid P, Kreipe HH, Harbeck N; WSG ADAPT investigators. Clinical and Molecular Biomarkers for Prediction of Endocrine Response after Short Preoperative Endocrine Therapy in the WSG ADAPT-HR+/HER2− and ADAPTcycle Trials (N = 7914). Ann Oncol. 2026 Apr 16:S0923-7534(26)00146-8. doi: 10.1016/j.annonc.2026.04.007. PMID: 41999978.
• Ganster F, Schrodi S, Braun M, Seifert C, Mahner S, Kolben T, Wuerstlein R, Harbeck N, Beyer S, Burgmann M. Tumor Biology, Treatment Patterns, and Recurrence in Breast Cancer Patients Aged 70–79 vs 80 Years: A Large-Scale Registry Analysis. Arch Gynecol Obstet. 2026 Mar 28;313(1):145. doi: 10.1007/s00404-026-08379-2.
• Braun M, Gluz O, Kuemmel S, Nitz U, Luedtke-Heckenkamp K, Darsow M, Forstbauer H, Polata S, Grischke EM, Uleer C, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Burmeister S, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N. Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT. Breast Care (Basel). 2026 Feb 12;21(2):140-51. doi: 10.1159/000550825. PMID: 41836917.
• Graeser M, Gluz O, Schmid P, Jóźwiak K, Zu Eulenburg C, Feuerhake F, Volk V, Ulbrich-Gebauer D, Biehl C, Reinisch M, Lüdtke-Heckenkamp K, Hartkopf A, Hilpert F, Braun M, Blohmer JU, Christgen M, Kreipe HH, Nitz U, Pelz E, Harbeck N, Kuemmel S. Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial. Clin Cancer Res. 2026 Jan 6;32(1):214-223. doi: 10.1158/1078-0432.CCR-25-1923.
• Kolberg HC, Schumacher J, Erber R, Braun M, Fasching PA, Grischke EM, Schem C, Lux MP, Deryal M, Hoffmann O, Heinrich B, Kunz G, Lübbe K, Krabisch P, Hartmann A, Räth P, Kasimir-Bauer S, Kolberg-Liedtke C. Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer – The neoMono Trial. Clin Cancer Res. 2025 Nov 14;31(22):4680-4687. doi: 10.1158/1078-0432.CCR-25-1288. PMID: 40932365.
• Graeser M, Gluz O, Zu Eulenburg C, Kuemmel S, von Schumann R, Christgen M, Wuerstlein R, Pelz E, Kreipe HH, Schmid P, Thill M, Braun M, Potenberg J, Schumacher C, Tio J, Schumacher J, Wujak L, Hartkopf AD, Just M, Schem C, Luedtke-Heckenkamp K, Hilpert F, Kentsch A, Kates RE, Nitz U, Harbeck N; West German Study Group investigators. Prediction of Survival after De-Escalated Neoadjuvant Therapy in HER2-Positive Early Breast Cancer: A Pooled Analysis of Three WSG Trials. Ann Oncol. 2025 Nov;36(11):1366-1378. doi: 10.1016/j.annonc.2025.07.016. PMID: 40769278.
• Hamann M, Christgen M, Gluz O, Nitz U, Kuemmel S, Braun M, Thill M, Wuerstlein R, Wimberger P, Hartkopf A, Schem C, Zaiss M, Bjelic-Radisic V, Just M, Veselinovic K, Vincent M, Graeser M, Krauss K, Hoffmann O, Lüdtke-Heckenkamp K, Kates RE, Zu Eulenburg C, Jóźwiak K, Burmeister S, Hauptmann M, Baehner F, Schmid P, Kreipe HH, Harbeck N. Endocrine Response Assessment in HR-Positive HER2-Negative Early Breast Cancer: Concordance of Local versus Central Ki67 Measurements in the WSG ADAPTcycle Trial (n = 5292). ESMO Open. 2025 Aug;10(8):105552. doi: 10.1016/j.esmoop.2025.105552.
• Hamann M, Bensmann E, Andrulat A, Festl J, Saadat G, Braun M. Real-World Quality of Life Outcomes after Prepectoral Implant-Based Breast Reconstruction with or without Titanium-Coated Mesh (TiLOOP Bra Pocket): A Prospective Cohort Study. Eur J Surg Oncol. 2025 Jul 4;51(10):110311. doi: 10.1016/j.ejso.2025.110311.
• Braun M, Hamann M, Hanusch C, Andrulat A, Bensmann E, Pölcher M, Beer M, Huber E. Evaluating the Impact of Histological vs. Nuclear Grading on CPS + EG Score for HR+/HER2− Early Breast Cancer. Breast Cancer Res Treat. 2025 Jun;211(3):699-704. doi: 10.1007/s10549-025-07685-8.
• Kuemmel S, Graeser M, Schmid P, Reinisch M, Feuerhake F, Volk V, Armeanu-Ebinger S, Schütz L, Kelemen O, Schroeder C, Ossowski S, Jóźwiak K, Kostara A, Scheffen I, Lüdtke-Heckenkamp K, Hilpert F, Kentsch A, Ziske C, Depenbusch R, Braun M, Blohmer JU, Zu Eulenburg C, Christgen M, Bartels S, Kreipe HH, Wuerstlein R, Biehl C, Pelz E, Hartkopf A, Harbeck N, Gluz O; West German Study Group investigators. Chemotherapy-Free Neoadjuvant Pembrolizumab Combined with Trastuzumab and Pertuzumab in HER2-Enriched Early Breast Cancer (WSG-KEYRICHED-1): A Single-Arm, Phase 2 Trial. Lancet Oncol. 2025 May;26(5):629-640. doi: 10.1016/S1470-2045(25)00097-X.
• Ganster F, Schrodi S, Braun M, Seifert C, Mahner S, Kolben T, Wuerstlein R, Harbeck N, Burgmann M. Breast Cancer in Patients under 40 Years: An 11-Year Retrospective Cohort Analysis. Arch Gynecol Obstet. 2025 May 15. doi: 10.1007/s00404-025-08031-5.
• Korbie D, Stirzaker C, Gluz O, Zu Eulenburg C, Nitz U, Christgen M, Kuemmel S, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Pelz E, Kreipe HH, Clark SJ, Trau M, Graeser M, Harbeck N. Immunomodulatory Gene Networks Predict Treatment Response and Survival to De-Escalated, Anthracycline-Free Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer in the WSG-ADAPT-TN Trial. Mol Cancer. 2025 Mar 26;24(1):96. doi: 10.1186/s12943-025-02275-0.
• Schmidt G, Gluz O, Christgen M, Reinisch M, Kümmel S, Nitz U, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Mahlberg R, Malter W, Reimer T, Nuding B, Stefek A, Wuerstlein R, Graeser M, Jóźwiak K, Burmeister S, Zu Eulenburg C, Lauseker M, Kolberg-Liedtke C, Prat A, Schmid P, Baehner R, Kreipe HH, Solomayer EF, Harbeck N; West German Study Group investigators. HER2-Low Status as a Distinct Breast Cancer Subtype: Myth or Truth? Analysis of the WSG Trials WSG-ADAPT-HR+/HER2−, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025 Feb 14;27(1):22. doi: 10.1186/s13058-025-01969-z. PMID: 39953511.
• Richters L, Gluz O, Weber-Lassalle N, Christgen M, Haverkamp H, Kuemmel S, Kayali M, Kates RE, Grischke EM, Altmüller J, Forstbauer H, Thiele H, Braun M, Warm M, Ossowski A, Wuerstlein R, Ernst C, Graeser M, Linn SC, Nitz U, Hauke J, Kreipe HH, Schmutzler RK, Hahnen E, Harbeck N. Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2025 Feb 3;8(2):e2461639. doi: 10.1001/jamanetworkopen.2024.61639.
• Martín M, Stecklein SR, Gluz O, Villacampa G, Monte-Millán M, Nitz U, Cobo S, Christgen M, Brasó-Maristany F, Álvarez EL, Echavarría I, Conte B, Kuemmel S, Bueno-Muiño C, Jerez Y, Kates R, Cebollero M, Kolberg-Liedtke C, Bueno O, García-Saenz JÁ, Moreno F, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Zu Eulenburg C, Kreipe HH, Gómez H, Massarrah T, Herrero B, Paré L, Bohn U, López-Tarruella S, Vivancos A, Sanfeliu E, Parker JS, Perou CM, Villagrasa P, Prat A, Sharma P, Harbeck N. TNBC-DX Genomic Test in Early-Stage Triple-Negative Breast Cancer Treated with Neoadjuvant Taxane-Based Therapy. Ann Oncol. 2025 Feb;36(2):158-171. doi: 10.1016/j.annonc.2024.10.012. PMID: 39419289.
• Hellerhoff K, Gottwald W, Taphorn K, Berthe D, Braun M, Wagner K, Resch S, John D, Heck L, Birnbacher L, Herzen J, Grandl S. Grating-Based X-Ray Dark-Field Mammography: Assessing Complementary Imaging Information in Simple Cystic Lesions and Typical Fibroadenoma. Med Phys. 2025 Jan 3. doi: 10.1002/mp.17603.
• Schönecker S, Angelini L, Gaasch A, Zinn A, Konnerth D, Heinz C, Xiong Y, Unger K, Landry G, Meattini I, Braun M, Pölcher M, Harbeck N, Würstlein R, Niyazi M, Belka C, Pazos M, Corradini S. Surface-Based Deep Inspiration Breath-Hold Radiotherapy in Left-Sided Breast Cancer: Final Results from the SAVE-HEART Study. ESMO Open. 2024 Dec;9(12):103993. doi: 10.1016/j.esmoop.2024.103993. PMID: 39631360.
• Hamann M, Bensmann E, Andrulat A, Festl J, Saadat G, Klein E, Chronas D, Braun M. Real-World Data of Perioperative Complications in Prepectoral Implant-Based Breast Reconstruction: A Prospective Cohort Study. Arch Gynecol Obstet. 2024 Dec;310(6):3077-3089. doi: 10.1007/s00404-024-07807-5. PMID: 39505750.
• Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, Braun M, Huober J, Jank P, Sinn HP, Zahm DM, Felder B, Hanusch C, Teply-Szymanski J, Marmé F, Fehm T, Thomalla J, Sinn BV, Stiewe T, Marczyk M, Blohmer JU, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover DG, Solbach C, Metzger-Filho O, Jackisch C, Geyer CE Jr, Fasching PA, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular Adaptation to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer. Cell Rep Med. 2024 Nov 19;5(11):101825. doi: 10.1016/j.xcrm.2024.101825.
• Harbeck N, Braun M, Gluz O, Schmid P, Graeser MK, Hartkopf AD, Hoffmann O, Kuemmel S, et al. Neoadjuvant Dynamic Marker-Adjusted Personalized Therapy Comparing Trastuzumab-Deruxtecan versus Pacli-/Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in HER2+ Early Breast Cancer: WSG-ADAPT-HER2-IV. J Clin Oncol. 2024;42(16 Suppl):TPS631. doi: 10.1200/JCO.2024.42.16_suppl.TPS631.
• Wolff J, Seidel S, Wuelfing P, Lux MP, Zu Eulenburg C, Smollich M, Baumann F, Seitz S, Kuemmel S, Thill M, Tio J, Braun M, Hollaender H, Seitz A, Horn F, Harbeck N, Wuerstlein R. App-Based Support for Breast Cancer Patients to Reduce Psychological Distress during Therapy and Survivorship – A Multicentric Randomized Controlled Trial. Front Oncol. 2024 Apr 18;14:1354377. doi: 10.3389/fonc.2024.1354377.
• Strauss M, Falk H, Braun M, Härtl K. Autogenes Training in der Behandlung von Brustkrebspatientinnen unter Chemotherapie: Ergebnisse einer Pilotstudie. Verhaltenstherapie & Verhaltensmedizin. 2024;2/2024. doi: 10.2440/006-0039.
• Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT investigators. De-Escalated Neoadjuvant Trastuzumab-Emtansine with or without Endocrine Therapy versus Trastuzumab with Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023 Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. PMID: 36809046.
• Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jóźwiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N. Nab-Paclitaxel Weekly versus Dose-Dense Solvent-Based Paclitaxel Followed by Dose-Dense Epirubicin plus Cyclophosphamide in High-Risk HR+/HER2− Early Breast Cancer: Results from the Neoadjuvant Part of the WSG-ADAPT-HR+/HER2− Trial. Ann Oncol. 2023 Jun;34(6):531-542. doi: 10.1016/j.annonc.2023.04.002.
• Rogowski P, Schönecker S, Konnerth D, Schäfer A, Pazos M, Gaasch A, Niyazi M, Boelke E, Matuschek C, Haussmann J, Braun M, Pölcher M, Würstlein R, Harbeck N, Belka C, Corradini S. Adjuvant Therapy for Elderly Breast Cancer Patients after Breast-Conserving Surgery: Outcomes in Real World Practice. Cancers (Basel). 2023 Apr 17;15(8):2334. doi: 10.3390/cancers15082334.
• Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, Christgen M, Palatty J, Kuemmel S, Grischke EM, Augustin D, Braun M, Potenberg J, Wuerstlein R, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Ni H, Kolberg-Liedtke C, Feuerhake F, Kreipe HH, Nitz U, Harbeck N. Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT-HER2+/HR− Trial. Clin Cancer Res. 2023 Feb 1;29(4):805-814. doi: 10.1158/1078-0432.CCR-22-1587.
• Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M; GBG and AGO-B. Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response. Ann Oncol. 2022 Nov;33(11):1149-1158. doi: 10.1016/j.annonc.2022.07.1940.
• Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, Harbeck N. Impact of Stromal Tumor-Infiltrating Lymphocytes (sTILs) on Response to Neoadjuvant Chemotherapy in Triple-Negative Early Breast Cancer in the WSG-ADAPT TN Trial. Breast Cancer Res. 2022 Sep 2;24(1):58. doi: 10.1186/s13058-022-01552-w.
• Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jóźwiak K, Zu Eulenburg C, Kreipe HH, Harbeck N. De-Escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Survival Analysis of the WSG-ADAPT-TN Trial. Clin Cancer Res. 2022 Nov 1;28(21):4756-4765. doi: 10.1158/1078-0432.CCR-22-0482. PMID: 35797219.
• Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Graeser M, Würstlein R, Shak S, Baehner F, Kreipe HH, Harbeck N; West German Study Group. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2− Early Breast Cancer. J Clin Oncol. 2022 May 10;40(14):1529-1540. doi: 10.1200/JCO.21.02759. PMID: 35404683.
• Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. De-Escalated Neoadjuvant Pertuzumab plus Trastuzumab Therapy with or without Weekly Paclitaxel in HER2-Positive, Hormone Receptor-Negative, Early Breast Cancer (WSG-ADAPT-HER2+/HR−): Survival Outcomes from a Multicentre, Open-Label, Randomised, Phase 2 Trial. Lancet Oncol. 2022 May;23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. PMID: 35405088.
• Braun M, Kriegmair A, Szeterlak N, Andrulat A, Schrodi S, Kriner M, Hanusch C, Hamann M, Stoetzer O, Pölcher M. Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level. Breast Care (Basel). 2022;17(3):288-295. doi: 10.1159/000521096.
• Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke EM, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H. TP53 Mutations Are Associated with Primary Endocrine Resistance in Luminal Early Breast Cancer. Cancer Med. 2021 Dec;10(23):8581-8594. doi: 10.1002/cam4.4376.
• Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, Klein E, Schnelzer A, Schindlbeck C, Bauerfeind I, Schubert-Fritschle G, Nekljudova V, Mayr D, Weichert W, Denkert C, Loibl S, Engel J. Outcome of Breast Cancer Patients with Low Hormone Receptor Positivity: Analysis of a 15-Year Population-Based Cohort. Ann Oncol. 2021 Nov;32(11):1410-1424. doi: 10.1016/j.annonc.2021.08.1988.
• Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, Forstbauer H, Tio J, Grischke EM, Biehl C, Liedtke C, De Haas SL, Deurloo R, Wuerstlein R, Kreipe HH, Gluz O. Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers (Basel). 2021 Sep 29;13(19):4884. doi: 10.3390/cancers13194884.
• Helbrich H, Braun M, Hanusch C, Mueller G, Falk H, Flondor R, Harbeck N, Hermelink K, Wuerstlein R, Keim S, Neufeld F, Steins-Loeber S, Haertl K. Congruence and Trajectories of Device-Measured and Self-Reported Physical Activity during Therapy for Early Breast Cancer. Breast Cancer Res Treat. 2021 Jul;188(2):351-359. doi: 10.1007/s10549-021-06195-7.
• Stoetzer O, Di Gioia D, Issels RD, Abdel-Rahman S, Mansmann U, Lindner LH, Gluz O, Würstlein R, Braun M, Hamann M, Edler von Koch F, Harbeck N, Salat C. Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. Breast Care (Basel). 2021 Apr;16(2):173-180. doi: 10.1159/000507473.
• Graeser M, Harbeck N, Gluz O, Würstlein R, Zu Eulenburg C, Schumacher C, Grischke EM, Forstbauer H, Dimpfl M, Braun M, Christgen M, Kreipe HH, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Kümmel S, Nitz U. The Use of Breast Ultrasound for Prediction of Pathologic Complete Response in Different Subtypes of Early Breast Cancer within the WSG-ADAPT Subtrials. Breast. 2021 Jun;58:58-66. doi: 10.1016/j.breast.2021.06.001.
• Graeser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, Jozwiak K, Christgen M, Kuemmel S, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe HH, Harbeck N. Immune Cell Composition and Functional Marker Dynamics from Multiplexed Immunohistochemistry to Predict Response to Neoadjuvant Chemotherapy in the WSG-ADAPT-TN Trial. J Immunother Cancer. 2021 May;9(5):e002198. doi: 10.1136/jitc-2020-002198.
• Graeser M, Schrading S, Gluz O, Strobel K, Herzog C, Umutlu L, Frydrychowicz A, Rjosk-Dendorfer D, Würstlein R, Culemann R, Zu Eulenburg C, Adams J, Nitzsche H, Prange A, Kümmel S, Grischke EM, Forstbauer H, Braun M, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U. Magnetic Resonance Imaging and Ultrasound for Prediction of Residual Tumor Size in Early Breast Cancer within the ADAPT Subtrials. Breast Cancer Res. 2021 Mar 18;23(1):36. doi: 10.1186/s13058-021-01413-y.
• Pölcher M, Braun M, Tischitz M, Hamann M, Szeterlak N, Kriegmair A, Brambs C, Becker C, Stoetzer O. Concordance of the Molecular Subtype Classification between Core Needle Biopsy and Surgical Specimen in Primary Breast Cancer. Arch Gynecol Obstet. 2021 Aug;304(2):449-456. doi: 10.1007/s00404-021-05996-x.
• Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, Schumacher C, Grischke EM, Forstbauer H, Braun M, Christgen M, Adams J, Nitzsche H, Just M, Fischer HH, Aktas B, Potenberg J, von Schumann R, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U. Early Response by MR Imaging and Ultrasound as Predictor of Pathologic Complete Response to 12-Week Neoadjuvant Therapy for Different Early Breast Cancer Subtypes: Combined Analysis from the WSG ADAPT Subtrials. Int J Cancer. 2021 May 15;148(10):2614-2627. doi: 10.1002/ijc.33495.
• Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N. The Run-In Phase of the Prospective WSG-ADAPT HR+/HER2− Trial Demonstrates the Feasibility of a Study Design Combining Static and Dynamic Biomarker Assessments for Individualized Therapy in Early Breast Cancer. Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130. doi: 10.1177/1758835920973130.
• Stoetzer O, Di Gioia D, Issels RD, Abdel-Rahman S, Mansmann U, Lindner LH, Gluz O, Würstlein R, Braun M, Hamann M, Edler von Koch F, Harbeck N, Salat C. Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. Breast Care (Basel). 2020;15(5):504-510. doi: 10.1159/000507473.
• Pölcher M, Matz S, Braun M, Brambs C, Beer M, Hamann M. Sentinel Lymph Node Mapping with Indocyanine Green Compared to Blue Dye Tracer in Gynecologic Malignancies – A Single Center Experience of 218 Patients. J Surg Oncol. 2021 Apr;123(4):890-897. doi: 10.1002/jso.26338.
• Gaasch A, Schönecker S, Simonetto C, Eidemüller M, Pazos M, Reitz D, Rottler M, Freislederer P, Braun M, Würstlein R, Harbeck N, Niyazi M, Belka C, Corradini S. Heart Sparing Radiotherapy in Breast Cancer: The Importance of Baseline Cardiac Risks. Radiat Oncol. 2020 May 24;15(1):117. doi: 10.1186/s13014-020-01520-8.
• Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N. Efficacy of Deescalated Chemotherapy according to PAM50 Subtypes, Immune and Proliferation Genes in Triple-Negative Early Breast Cancer: Primary Translational Analysis of the WSG-ADAPT-TN Trial. Int J Cancer. 2020 Jan 1;146(1):262-271. doi: 10.1002/ijc.32488.
• Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603.
• Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457.
• Hamann M, Brunnbauer M, Scheithauer H, Hamann U, Braun M, Pölcher M. Quality of Life in Breast Cancer Patients and Surgical Results of Immediate Tissue Expander/Implant-Based Breast Reconstruction after Mastectomy. Arch Gynecol Obstet. 2019 Aug;300(2):409-420. doi: 10.1007/s00404-019-05201-0.
• Simonetto C, Eidemüller M, Gaasch A, Pazos M, Schönecker S, Reitz D, Kääb S, Braun M, Harbeck N, Niyazi M, Belka C, Corradini S. Does Deep Inspiration Breath-Hold Prolong Life? Individual Risk Estimates of Ischaemic Heart Disease after Breast Cancer Radiotherapy. Radiother Oncol. 2019 Feb;131:202-207. doi: 10.1016/j.radonc.2018.07.024.
• Meissner K, Talsky N, Olliges E, Jacob C, Stötzer OJ, Salat C, Braun M, Flondor R. Individual Factors Contributing to Nausea in First-Time Chemotherapy Patients: A Prospective Cohort Study. Front Pharmacol. 2019 Apr 25;10:410. doi: 10.3389/fphar.2019.00410.
• Rogowski P, Schönecker S, Pazos M, Reitz D, Braun M, Pölcher M, Hanusch C, Wuerstlein R, Harbeck N, Mahner S, Belka C, Corradini S. Pattern of Care of Adjuvant Radiotherapy in Male Breast Cancer Patients in Clinical Practice: An Observational Study. Strahlenther Onkol. 2019 Apr;195(4):289-296. doi: 10.1007/s00066-018-1337-8.
• Corradini S, Reitz D, Pazos M, Schönecker S, Braun M, Harbeck N, Matuschek C, Bölke E, Ganswindt U, Alongi F, Niyazi M, Belka C. Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. Cancers (Basel). 2019 Jan 31;11(2):160. doi: 10.3390/cancers11020160.
• Pazos M, Schönecker S, Reitz D, Rogowski P, Niyazi M, Alongi F, Matuschek C, Braun M, Harbeck N, Belka C, Corradini S. Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. Breast Care (Basel). 2018 Aug;13(4):285-291. doi: 10.1159/000488189.
• Brugger S, Hamann M, Mosner M, Beer M, Braun M, Pölcher M. Endometrial Cancer – How Many Patients Could Benefit from Sentinel Lymph Node Dissection? World J Surg Oncol. 2018 May 17;16(1):95. doi: 10.1186/s12957-018-1392-8.
• Corradini S, Pazos M, Schönecker S, Reitz D, Niyazi M, Ganswindt U, Schrodi S, Braun M, Pölcher M, Mahner S, Harbeck N, Engel J, Belka C. Role of Postoperative Radiotherapy in Reducing Ipsilateral Recurrence in DCIS: An Observational Study of 1048 Cases. Radiat Oncol. 2018 Feb 9;13(1):25. doi: 10.1186/s13014-018-0964-7.
• Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N. Comparison of Neoadjuvant Nab-Paclitaxel + Carboplatin vs Nab-Paclitaxel + Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258. PMID: 29228315.
• Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT Investigators. De-Escalation Strategies in HER2-Positive Early Breast Cancer (EBC): Final Analysis of the WSG-ADAPT HER2+/HR− Phase II Trial: Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Dual Blockade with Trastuzumab and Pertuzumab ± Weekly Paclitaxel. Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494. PMID: 28945833.
• Hermelink K, Bühner M, Sckopke P, Neufeld F, Kaste J, Voigt V, Münzel K, Wuerstlein R, Ditsch N, Hellerhoff K, Rjosk-Dendorfer D, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Mahner S, Harbeck N. Chemotherapy and Post-Traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. J Natl Cancer Inst. 2017 Oct 1;109(10):djx057. doi: 10.1093/jnci/djx057.
• Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Kümmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA. De-Escalation Strategies in HER2-Positive Early Breast Cancer: Final Analysis of the WSG-ADAPT HER2+/HR+ Phase II Randomized Trial – Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine with or without Endocrine Therapy versus Trastuzumab plus Endocrine Therapy. J Clin Oncol. 2017 Sep 1;35(25):2960-2967. doi: 10.1200/JCO.2016.71.9815.
• Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Harbeck N, Engel J. Improved Systemic Treatment for Early Breast Cancer Improves Cure Rates, Modifies Metastatic Pattern and Shortens Post-Metastatic Survival: 35-Year Results from the Munich Cancer Registry. J Cancer Res Clin Oncol. 2017 Jun;143(6):1077-1088. doi: 10.1007/s00432-017-2364-9.
• Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Harbeck N, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Engel J. Survival of De Novo Stage IV Breast Cancer Patients over Three Decades. J Cancer Res Clin Oncol. 2017 Mar;143(3):509-519. doi: 10.1007/s00432-016-2297-y.
• Corradini S, Bauerfeind I, Belka C, Braun M, Combs SE, Eckel R, Harbeck N, Hölzel D, Kiechle M, Niyazi M, Engel J. Trends in Use and Outcome of Postoperative Radiotherapy following Mastectomy: A Population-Based Study. Radiother Oncol. 2017 Jan;122(1):2-10. doi: 10.1016/j.radonc.2016.09.012.
• Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevalence of BRCA1/2 Germline Mutations in 21 401 Families with Breast and Ovarian Cancer. J Med Genet. 2016 Jul;53(7):465-471. doi: 10.1136/jmedgenet-2015-103672.
• Debald M, Abramian A, Nemes L, Döbler M, Kaiser C, Keyver-Paik MD, Leutner C, Höller T, Braun M, Kuhl C, Kuhn W, Schild HH. Who May Benefit from Preoperative Breast MRI? A Single-Center Analysis of 1102 Consecutive Patients with Primary Breast Cancer. Breast Cancer Res Treat. 2015 Oct;153(3):531-537. doi: 10.1007/s10549-015-3566-7.
• Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Bühner M, Münzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N. Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-Related Post-Traumatic Stress. J Natl Cancer Inst. 2015 Apr 16;107(7):djv099. doi: 10.1093/jnci/djv099.
• Brugger S, Hamann U, Alberti W, von Obernitz N, Braun M, Pölcher M. Stellenwert minimal-invasiver Technik: Verdrängt die laparoskopische Hysterektomie die vaginale Hysterektomie? Geburtshilfe Frauenheilkd. 2014;74(Suppl 01).
• Debald M, Wolfgarten M, Kreklau P, Abramian A, Kaiser C, Höller T, Leutner C, Keyver-Paik MD, Braun M, Kuhn W. Staging of Primary Breast Cancer Is Not Indicated in Asymptomatic Patients with Early Tumor Stages. Oncol Res Treat. 2014;37(7-8):400-405. doi: 10.1159/000365086.
• Debald M, Kaiser C, Abramian A, Schildhaus HU, Locher P, Wolfgarten M, Kuhn W, Braun M. Evaluation of E-Cadherin, Ki-67 and Lymphatic Vessel Invasion in Abdominal Metastases of Human Breast Cancer. Anticancer Res. 2013 May;33(5):1971-1975.
• Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients by Circulating Apoptotic Biomarkers Nucleosomes, DNAse, Cytokeratin-18 Fragments and Survivin. Cancer Lett. 2013 Jul 28;336(1):140-148. doi: 10.1016/j.canlet.2013.04.013.
• Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Circulating Immunogenic Cell Death Biomarkers HMGB1 and RAGE in Breast Cancer Patients during Neoadjuvant Chemotherapy. Tumour Biol. 2013 Feb;34(1):81-90. doi: 10.1007/s13277-012-0518-6.
• Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH. Risk Assessment, Disease Prevention and Personalised Treatments in Breast Cancer: Is Clinically Qualified Integrative Approach in the Horizon? EPMA J. 2013 Feb 19;4(1):6. doi: 10.1186/1878-5085-4-6.
• Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, Jaehde U. Pharmaceutical Care for Patients with Breast and Ovarian Cancer. Support Care Cancer. 2012 Nov;20(11):2669-2677. doi: 10.1007/s00520-012-1398-5.
• Weber SK, Sauerwald A, Pölcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G, Rudlowski C. Detection of Lymphovascular Invasion by D2-40 (Podoplanin) Immunoexpression in Endometrial Cancer. Int J Gynecol Cancer. 2012 Oct;22(8):1442-1448. doi: 10.1097/IGC.0b013e31826b9d30.
• Debald M, Franken S, Heukamp LC, Linke A, Wolfgarten M, Walgenbach KJ, Braun M, Rudlowski C, Gieselmann V, Kuhn W, Hartmann G, Walgenbach-Brünagel G. Identification of Specific Nuclear Structural Protein Alterations in Human Breast Cancer. J Cell Biochem. 2011 Nov;112(11):3176-3184. doi: 10.1002/jcb.23245.
• Kühr M, Wolfgarten M, Stölzle M, Leutner C, Höller T, Schrading S, Kuhl C, Schild H, Kuhn W, Braun M. Potential Impact of Preoperative Magnetic Resonance Imaging of the Breast on Patient Selection for Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e541-e546. doi: 10.1016/j.ijrobp.2011.05.065.
• Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U. Enhancing Adherence to Capecitabine Chemotherapy by Means of Multidisciplinary Pharmaceutical Care. Support Care Cancer. 2011 Jul;19(7):1009-1018. doi: 10.1007/s00520-010-0927-1.
• Walgenbach KJ, Kuhl C, Rudlowski C, Poelcher M, Sauerwald A, Walgenbach-Brünagel G, Kuhn W, Braun M. A Rare Complication Following Breast Implant Surgery: Capsular Contracture with a Cutaneous Silicone Fistula after Breast Reconstruction with Silicone Gel Implants. Breast Care (Basel). 2011;6(1):51-53. doi: 10.1159/000324822.
• Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O. Noninvasive Subcellular Imaging in Breast Cancer Risk Assessment: Construction of Diagnostic Windows. Personalized Med. 2011;8(3):321-330. doi: 10.2217/pme.11.26.
• Debald M, Pölcher M, Flucke U, Walgenbach-Bruenagel G, Walgenbach KJ, Höller T, Wolfgarten M, Rudlowski C, Büttner R, Schild H, Kuhn W, Braun M. Increased Detection of Lymphatic Vessel Invasion by D2-40 (Podoplanin) in Early Breast Cancer: Possible Influence on Patient Selection for Accelerated Partial Breast Irradiation (APBI). Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1128-1133. doi: 10.1016/j.ijrobp.2009.05.065.
• Flucke U, Flucke MT, Hoy L, Breuer E, Goebbels R, Rhiem K, Schmutzler R, Winzenried H, Braun M, Steiner S, Buettner R, Gevensleben H. Distinguishing Medullary Carcinoma of the Breast from High-Grade Hormone Receptor-Negative Invasive Ductal Carcinoma: An Immunohistochemical Approach. Histopathology. 2010 Jun;56(7):852-859. doi: 10.1111/j.1365-2559.2010.03544.x.
• Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, Kuhn WC, Hernando JJ. Foxp3+ Cell Infiltration and Granzyme B+/Foxp3+ Cell Ratio Are Associated with Outcome in Neoadjuvant Chemotherapy-Treated Ovarian Carcinoma. Cancer Immunol Immunother. 2010 Jun;59(6):909-919. doi: 10.1007/s00262-009-0797-9.
• Schrading S, Simon B, Braun M, Wardelmann E, Schild HH, Kuhl CK. MRI-Guided Breast Biopsy: Influence of Choice of Vacuum Biopsy System on the Mode of Biopsy of MRI-Only Suspicious Breast Lesions. AJR Am J Roentgenol. 2010 Jun;194(6):1650-1657. doi: 10.2214/AJR.09.2754.
• Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höller T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M. Impact of the Menstrual Cycle on Circulating Cell-Free DNA. Anticancer Res. 2010 Jun;30(6):2235-2240.
• Pölcher M, Friedrichs N, Rudlowski C, Fimmers R, Keyver-Paik MD, Kübler K, Sauerwald A, Büttner R, Kuhn W, Braun M. Changes in Ki-67 Labelling Indices during Neoadjuvant Chemotherapy for Advanced Ovarian Cancer Are Associated with Survival. Int J Gynecol Cancer. 2010 May;20(4):555-560. doi: 10.1111/IGC.0b013e3181d4a84d.
• Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höller T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M. In Vivo Intratumor Angiogenic Treatment Effects during Taxane-Based Neoadjuvant Chemotherapy of Ovarian Cancer. BMC Cancer. 2010 Apr 13;10:137. doi: 10.1186/1471-2407-10-137.
• Mallmann M, Staratschek-Jox A, Rudlowski C, Braun M, Kuhn W, Schultze J. Prediction and Prognosis: Impact of Gene Expression Profiling in Personalized Treatment of Breast Cancer Patients. EPMA J. 2010;1(3):413-420. doi: 10.1007/s13167-010-0043-7.
• Debald M, Walgenbach-Brünagel G, Braun M. Non-Invasive Proteomics – Thinking about Personalized Breast Cancer Screening and Treatment. EPMA J. 2010;1(3):421-426. doi: 10.1007/s13167-010-0044-6.
• Braun M, Wardelmann E, Debald M, Walgenbach-Brunagel G, Höller T, Wolfgarten M, Sauerwald A, Rudlowski C, Büttner R, Kuhn W, Pölcher M. Detection of Lymphovascular Invasion in Vulvar Cancer by D2-40 (Podoplanin) as a Predictor for Inguinal Lymph Node Metastases. Onkologie. 2009 Dec;32(12):732-738. doi: 10.1159/000245174.
• Pölcher M, Mahner S, Ortmann O, Hilfrich J, Braun M, Kuhn W. Neoadjuvant Chemotherapy with Carboplatin and Docetaxel in Advanced Ovarian Cancer – A Prospective Multicenter Phase 2 Trial (PRIMOVAR). Oncol Rep. 2009 Sep;22(3):605-613. doi: 10.3892/or_00000481.
• Braun M, Fountoulakis M, Seidel I, Höller T, Yeghiazaryan K, Schild H, Kuhn W, Golubnitschaja O. Down-Regulation of Microfilamental Network-Associated Proteins in Leukocytes of Breast Cancer Patients: Potential Application to Predictive Diagnosis. Cancer Genomics Proteomics. 2009;6(1):31-40.
• Braun M, Jacobs VR, Wagenpfeil S, Sattler D, Bernard R, Kuhn W, Ihbe-Heffinger A. Cost-Cost Analysis Comparing an Anthracycline/Docetaxel Regime to CMF in Patients with Early Stage Breast Cancer. Onkologie. 2009;32(8-9):473-481. doi: 10.1159/000228922.
• Braun M, Pölcher M, Schrading S, Zivanovic O, Kowalski T, Flucke U, Leutner C, Park-Simon TW, Rudlowski C, Kuhn W, Kuhl CK. Influence of Preoperative MRI on the Surgical Management of Patients with Operable Breast Cancer. Breast Cancer Res Treat. 2008 Sep;111(1):179-187. doi: 10.1007/s10549-007-9771-0.
• Kuhl C, Braun M. Magnetic Resonance Imaging in Preoperative Staging for Breast Cancer: Pros and Contras. Radiologe. 2008 Apr;48(4):358-366. doi: 10.1007/s00117-008-1637-5.
• Wollenschein M, van der Ven K, Montag M, Braun M, Rohde A. Fertilitätsprotektion bei onkologischen Patientinnen: Kryobank Bonn – Beratung, Anwendung und die Bedeutung für die betroffene Frau. Geburtsh Frauenheilk. 2008;68:262-267.
• Wollenschein M, Montag MM, van der Ven K, Braun M, Rohde A. Cancer Female Patients with Desire to Have Children: Significance of Cryopreservation of the Ovary Tissues – An Example of Cryobank Bonn. Geburtsh Frauenheilk. 2008;68:188-189.
• Braun M, Flucke U, Debald M, Walgenbach-Bruenagel G, Walgenbach KJ, Höller T, Pölcher M, Wolfgarten M, Sauerwald A, Keyver-Paik M, Kühr M, Büttner R, Kuhn W. Detection of Lymphovascular Invasion in Early Breast Cancer by D2-40 (Podoplanin): A Clinically Useful Predictor for Axillary Lymph Node Metastases. Breast Cancer Res Treat. 2008;112(3):503-511. doi: 10.1007/s10549-007-9876-5.
• Kuhl CK, Kuhn W, Braun M, Schild H. Pre-Operative Staging of Breast Cancer with Breast MRI: One Step Forward, Two Steps Back? Breast. 2007 Oct;16(Suppl 1):S34-S44. doi: 10.1016/j.breast.2007.07.012.
• Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Pölcher M, Grunn U, Leutner C, Pötsch B, Kuhn W. Vaccination with Dendritic Cells Transfected with mRNA-Encoded Folate-Receptor-Alpha for Relapsed Metastatic Ovarian Cancer. Lancet Oncol. 2007 May;8(5):451-454. doi: 10.1016/S1470-2045(07)70136-7.
• Braun M, Schlehe B, Faridi A, Heinrichs U, Rudlowski C. Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – A Pilot Study. Breast Care (Basel). 2007;2(4):227-233. doi: 10.1159/000104484.
• Yeghiazaryan K, Mamlouk S, Trog D, Moenkemann H, Braun M, Kuhn W, Schild H, Golubnitschaja O. Irradiated Breast Cancer Patients Demonstrate Subgroup Specific Regularities in Protein Expression Patterns of Circulating Leukocytes. Cancer Genomics Proteomics. 2007;4(6):411-418.
• Zivanovic O, Braun M, Park TW, Kuhn W. The Impact of the Pathologist on the Treatment of Epithelial Ovarian Cancer. Verh Dtsch Ges Pathol. 2005;89:101-110.
• Braun M, Schelling M, Kuhn W, Ulm K, Rutke S, Graeff H. Combination of B-Mode and Color Doppler Sonography for Differential Diagnoses of Breast Lesions. Geburtsh Frauenheilk. 2001;61:2-6.
• Schelling M, Braun M, Kuhn W, Bogner G, Gruber R, Gnirs J, Schneider KTM, Ulm K, Rutke S, Staudach A. Combined Transvaginal B-Mode and Color Doppler Sonography for Differential Diagnosis of Ovarian Tumors: Results of a Multivariate Logistic Regression Analysis. Gynecol Oncol. 2000 Apr;77(1):78-86. doi: 10.1006/gyno.2000.5724.
• Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M, Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Janicke F. Tumor-Biological Factors uPA and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer. Int J Biol Markers. 2000 Jan-Mar;15(1):73-78.
• Schelling M, Gnirs J, Braun M, Busch R, Maurer S, Kuhn W, Schneider KTM, Graeff H. Optimized Differential Diagnosis of Breast Lesions by Combined B-Mode and Color Doppler Sonography. Ultrasound Obstet Gynecol. 1997;10:48-53. doi: 10.1046/j.1469-0705.1997.10010048.x.

• 2026: Auszeichnung als Top-Mediziner im Fachgebiet Brustkrebs durch FOCUS-Gesundheit
• 2025/2026: Auszeichnung im Fachbereich Ästhetische Brustchirurgie durch stern-Ärzteliste
• 2025: Auszeichnung als Top-Mediziner im Fachgebiet Brustkrebs durch FOCUS-Gesundheit
• 2024: Auszeichnung als Top-Mediziner im Fachgebiet Brustkrebs durch FOCUS-Gesundheit
• 2023: Auszeichnung als Top-Mediziner im Fachgebiet Brustkrebs durch FOCUS-Gesundheit
• 2022: Auszeichnung als Top-Mediziner im Fachgebiet Brustkrebs durch FOCUS-Gesundheit